Karyopharm Therapeutics Statistics
Share Statistics
Karyopharm Therapeutics has 8.64M
shares outstanding. The number of shares has increased by 0.8%
in one year.
| Shares Outstanding | 8.64M |
| Shares Change (YoY) | 0.8% |
| Shares Change (QoQ) | -0.46% |
| Owned by Institutions (%) | 48.73% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 205 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 1.98M, so 23.09% of the outstanding
shares have been sold short.
| Short Interest | 1.98M |
| Short % of Shares Out | 23.09% |
| Short % of Float | 23.27% |
| Short Ratio (days to cover) | 22.34 |
Valuation Ratios
The PE ratio is -16.17 and the forward
PE ratio is -0.68.
Karyopharm Therapeutics's PEG ratio is
0.33.
| PE Ratio | -16.17 |
| Forward PE | -0.68 |
| PS Ratio | 8.51 |
| Forward PS | 0.1 |
| PB Ratio | -6.64 |
| P/FCF Ratio | -9.68 |
| PEG Ratio | 0.33 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Karyopharm Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.7,
with a Debt / Equity ratio of -1.05.
| Current Ratio | 1.7 |
| Quick Ratio | 1.64 |
| Debt / Equity | -1.05 |
| Debt / EBITDA | -5.04 |
| Debt / FCF | -1.52 |
| Interest Coverage | -3.19 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $520,562.72 |
| Profits Per Employee | $-273,913.98 |
| Employee Count | 279 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 1.27 |
Taxes
| Income Tax | 57K |
| Effective Tax Rate | -0.07% |
Stock Price Statistics
The stock price has increased by -69.46% in the
last 52 weeks. The beta is 0.33, so Karyopharm Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.33 |
| 52-Week Price Change | -69.46% |
| 50-Day Moving Average | 5.46 |
| 200-Day Moving Average | 9.75 |
| Relative Strength Index (RSI) | 43.94 |
| Average Volume (20 Days) | 135,100 |
Income Statement
In the last 12 months, Karyopharm Therapeutics had revenue of 145.24M
and earned -76.42M
in profits. Earnings per share was -0.63.
| Revenue | 145.24M |
| Gross Profit | 139.23M |
| Operating Income | -119.44M |
| Net Income | -76.42M |
| EBITDA | -38.6M |
| EBIT | -38.94M |
| Earnings Per Share (EPS) | -0.63 |
Full Income StatementBalance Sheet
The company has 62.48M in cash and 194.52M in
debt, giving a net cash position of -132.05M.
| Cash & Cash Equivalents | 62.48M |
| Total Debt | 194.52M |
| Net Cash | -132.05M |
| Retained Earnings | -1.56B |
| Total Assets | 127.71M |
| Working Capital | 29.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -127.49M
and capital expenditures -142K, giving a free cash flow of -127.63M.
| Operating Cash Flow | -127.49M |
| Capital Expenditures | -142K |
| Free Cash Flow | -127.63M |
| FCF Per Share | -1.05 |
Full Cash Flow StatementMargins
Gross margin is 95.86%, with operating and profit margins of -82.24% and -52.62%.
| Gross Margin | 95.86% |
| Operating Margin | -82.24% |
| Pretax Margin | -52.58% |
| Profit Margin | -52.62% |
| EBITDA Margin | -26.58% |
| EBIT Margin | -82.24% |
| FCF Margin | -87.88% |
